Table 5.
Reported effects of β-carotene supplementation in CF
| Final plasma β-carotene (μmol/l) | Study period | Oxidative stress |
Inflammation |
ATB, days | Lung function, FEV1 | Weight* height† z score | Ref. No. | |||
|---|---|---|---|---|---|---|---|---|---|---|
| (months) | MDA | LDL | 8-iso-PGF2α | NE/α1-PI | TNFα | |||||
| 1.07±0.86 | 3 | ↓ | ↓ | - | - | - | - | - | - | [104] |
| 1.07±0.19 | 18 | ↓ | - | - | ↓ | ↓ | - | - | ↑* | [118] |
| 3.99±0.92 | 2 | ↓ | - | - | - | - | - | - | - | [105] |
| 0.60±0.40 | 3 | ↓ | - | - | - | - | ↓ | - | - | [119] |
| 0.30±0.20 | 6 | NS | - | - | - | - | NS | NS | ↑† | [119] |
| 0.07 to 1.63 | 6 | ↓ | - | - | - | ↓ | - | ↑ | - | [108] |
| Δ0.1±0.04 | 2 | - | - | NS | - | - | NS | NS | - | [109] |
MDA, malondialdehyde; LDL, low-density lipoprotein oxidation; 8-iso-PGF2α, 8-iso-prostaglandin F(2)α; NE/α1-PI, neutrophil elastase/α1-PI; TNFα, tumor necrosis factor α; ATB, antibiotic treatment; FEV1, forced expiratory volume in 1 s.